- Home
- IBCP vs DNTH Comparison
IBCP vs DNTH Comparison
Compare IBCP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- DNTH
- Stock Information
- Founded
- IBCP 1864
- DNTH 2015
- Country
- IBCP United States
- DNTH United States
- Employees
- IBCP N/A
- DNTH N/A
- Industry
- IBCP Major Banks
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- IBCP Finance
- DNTH Health Care
- Exchange
- IBCP Nasdaq
- DNTH Nasdaq
- Market Cap
- IBCP 795.2M
- DNTH 823.1M
- IPO Year
- IBCP N/A
- DNTH N/A
- Fundamental
- Price
- IBCP $37.74
- DNTH $23.36
- Analyst Decision
- IBCP Hold
- DNTH Strong Buy
- Analyst Count
- IBCP 3
- DNTH 8
- Target Price
- IBCP $32.17
- DNTH $46.43
- AVG Volume (30 Days)
- IBCP 111.9K
- DNTH 292.8K
- Earning Date
- IBCP 10-24-2024
- DNTH 11-07-2024
- Dividend Yield
- IBCP 2.54%
- DNTH N/A
- EPS Growth
- IBCP 3.52
- DNTH N/A
- EPS
- IBCP 2.94
- DNTH N/A
- Revenue
- IBCP $208,212,000.00
- DNTH $5,366,000.00
- Revenue This Year
- IBCP N/A
- DNTH $44.94
- Revenue Next Year
- IBCP $5.96
- DNTH N/A
- P/E Ratio
- IBCP $12.84
- DNTH N/A
- Revenue Growth
- IBCP 3.25
- DNTH 51.41
- 52 Week Low
- IBCP $20.50
- DNTH $6.58
- 52 Week High
- IBCP $39.52
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- IBCP 63.08
- DNTH 29.54
- Support Level
- IBCP $31.79
- DNTH $27.41
- Resistance Level
- IBCP $39.52
- DNTH $28.56
- Average True Range (ATR)
- IBCP 1.20
- DNTH 1.86
- MACD
- IBCP 0.38
- DNTH -0.50
- Stochastic Oscillator
- IBCP 76.97
- DNTH 11.61
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.